This company listing is no longer active
Resumen de acción CCXI
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.
Puntuación del snowflake | |
---|---|
Valoración | 2/6 |
Crecimiento futuro | 5/6 |
Rendimiento pasado | 0/6 |
Salud financiera | 4/6 |
Dividendos | 0/6 |
Competidores de ChemoCentryx, Inc.
Historial de precios y rendimiento
Precios históricos de las acciones | |
---|---|
Precio actual de la acción | US$51.99 |
Máximo en las últimas 52 semanas | US$52.00 |
Mínimo de 52 semanas | US$14.95 |
Beta | 1.23 |
1Cambio en 1 mes | 0.41% |
Variación en 3 meses | 134.51% |
Cambio de 1 año | 50.39% |
3Variación en 3 años | 558.10% |
Variación en 5 años | 642.71% |
Variación desde la OPV | 372.64% |
Noticias y actualizaciones recientes
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09Recent updates
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09ChemoCentryx: Revisiting The Investment Case
Jun 21ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Jun 06ChemoCentryx: Good Post-Approval Performance, But Needs More Time
Mar 03ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Feb 11Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week
Jan 21Checking In On ChemoCentryx
Dec 15Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?
Oct 09ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way
Sep 29ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
Aug 24Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook
Aug 11ChemoCentryx: CRL Less Likely
Jul 25ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price
Jul 11ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jun 15ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress
Jun 08ChemoCentryx: CRL Likely
May 09ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action
May 07Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate
May 04When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?
Mar 03ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 04ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price
Jan 14Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?
Dec 31Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)
Dec 23ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study
Dec 21Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?
Dec 13Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?
Nov 22ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10Rentabilidad de los accionistas
CCXI | US Biotechs | Mercado US | |
---|---|---|---|
7D | 0.1% | 0.1% | 0.07% |
1Y | 50.4% | 14.0% | 22.7% |
Rentabilidad vs. Industria: CCXI exceeded the US Biotechs industry which returned -1.9% over the past year.
Rentabilidad vs. Mercado: CCXI exceeded the US Market which returned -19.8% over the past year.
Volatilidad de los precios
CCXI volatility | |
---|---|
CCXI Average Weekly Movement | 31.3% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: CCXI's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: CCXI's weekly volatility has increased from 18% to 31% over the past year.
Acerca de la empresa
Fundada | Empleados | CEO | Página web |
---|---|---|---|
1996 | 178 | n/a | www.chemocentryx.com |
Resumen de fundamentos de ChemoCentryx, Inc.
Estadísticas fundamentales de CCXI | |
---|---|
Capitalización bursátil | US$3.74b |
Beneficios(TTM) | -US$133.09m |
Ingresos (TTM) | US$37.28m |
100.3x
Ratio precio-ventas (PS)-28.1x
Ratio precio-beneficio (PE)¿Está CCXI sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
Cuenta de resultados (TTM) de CCXI | |
---|---|
Ingresos | US$37.28m |
Coste de los ingresos | US$71.86m |
Beneficio bruto | -US$34.58m |
Otros gastos | US$98.51m |
Beneficios | -US$133.09m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) | -1.85 |
Margen bruto | -92.76% |
Margen de beneficio neto | -357.01% |
Ratio deuda/patrimonio | 10.5% |
¿Cómo se ha desempeñado CCXI a largo plazo?
Ver rendimiento histórico y comparativa